Evento

Addition of cabergoline to trilostane treatment for dogs with pituitary-dependent hypercortisolism

Golinelli, Stefania; Fracassi, Federico; Gomes Pöppl, Alan; De Marco, Viviani; Miceli, Diego DanielIcon ; Seo, Kyoung won; Feldman, Edward C.
Colaboradores: Schuller, Simone
Tipo del evento: Congreso
Nombre del evento: 2023 ECVIM-CA Congress
Fecha del evento: 21/09/2023
Institución Organizadora: European Coleege of Veterinary Internal Medicina;
Título de la revista: Journal Of Veterinary Internal Medicine
Editorial: John Wiley & Sons
ISSN: 0891-6640
e-ISSN: 1939-1676
Idioma: Inglés
Clasificación temática:

Resumen

Trilostane (T) is usually effective in controlling the hypercortisolemic state in canine pituitary-dependent hypercortisolism (PDH), however, its effect on pituitary tumor (PT) function and growth has not been reported. Cabergoline (C), a dopamine agonist, is a potential “pituitary-targeting” drug.
Palabras clave: CABERGOLINE , TRILOSTANE , HYPERCORTISOLISM , CUSHING SYNDROME
 
Archivos asociados
Thumbnail
 
Tamaño: 329.9Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/254936
URL: https://onlinelibrary.wiley.com/doi/10.1111/jvim.16930
DOI: https://doi.org/10.1111/jvim.16930
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Addition of cabergoline to trilostane treatment for dogs with pituitary-dependent hypercortisolism; 2023 ECVIM-CA Congress; Barcelona; España; 2023; 766-766
Compartir
Altmétricas